ArticleJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry2014
Contrast agents for MRI: 30+ years and where are we going?
Article in Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 167 citations in OpenAlex.
- Magnetic resonance and X-ray contrast agents in the optical clearing of dermis - insights fromBiomedical optics express · 2026Article
- High-resolution quantitative mapping of extracellular pH by ratiometric MRI with iron chelates in a tumor mouse model.La Radiologia medica · 2025Article
- Gadolinium-Based Contrast Agents (GBCAs) for MRI: A Benefit-Risk Balance Analysis from a Chemical, Biomedical, and Environmental Point of View.Global challenges (Hoboken, NJ) · 2025Review
- New Processes for Ionizing Nonvolatile Compounds in Mass Spectrometry: The Road of Discovery to Current State-of-the-Art.Journal of the American Society for Mass Spectrometry · 2024Review
- Activatable near-infrared fluorescence and chemical exchange saturation transfer MRI multimodal imaging probe for tumor detection in vitro and in vivo.Sensors and actuators. B, Chemical · 2024Article
- Seeking for Innovation with Magnetic Resonance Imaging Paramagnetic Contrast Agents: Relaxation Enhancement via Weak and Dynamic Electrostatic Interactions with Positively Charged Groups on Endogenous Macromolecules.Journal of the American Chemical Society · 2024Article
- Gd(III) and Yb(III) Complexes Derived from a New Water-Soluble Dioxopolyazacyclohexane Macrocycle.ACS omega · 2023Article
- Contrast Agents of Magnetic Resonance Imaging and Future Perspective.Nanomaterials (Basel, Switzerland) · 2023Review
- Gadolinium-Cyclic 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Click-Sulfonyl Fluoride for Probing Serine Protease Activity in Magnetic Resonance Imaging.Molecules (Basel, Switzerland) · 2023Article
- Non-radioactive imaging strategies forPhysical sciences reviews · 2023Article
- Tuning the pH of Activation of Fluorinated Hydrazone-Based Switches─A Pathway to VersatileACS sensors · 2023Article
- Theranostics with photodynamic therapy for personalized medicine: to see and to treat.Theranostics · 2023Review
- Gadolinium Accumulation and Toxicity on In Vitro GrownInternational journal of molecular sciences · 2022Article
- The interaction between iodinated X-ray contrast agents and macrocyclic GBCAs provides a signal enhancement in TMagnetic resonance in medicine · 2022Article
- Identification of seven-coordinate LnJournal of chemical crystallography · 2022Article
- Ratiometric pH-ResponsiveAnalytical chemistry · 2022Article
- PEGylation of Metal Oxide Nanoparticles Modulates Neutrophil Extracellular Trap Formation.Biosensors · 2022Article
- Iron(iii) chelated paramagnetic polymeric nanoparticle formulation as a next-generationRSC advances · 2021Article
- Dynamic Contrast Enhancement (DCE) MRI-Derived Renal Perfusion and Filtration: Basic Concepts.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Targeted PET/MRI Imaging Super Probes: A Critical Review of Opportunities and Challenges.International journal of nanomedicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Thirty years ago, Schering filed the first patent application for a contrast agent for magnetic resonance imaging (MRI) covering the forefather of the gadolinium contrast agents and still the most widely used gadolinium probe: gadolinium(III) diethylenetriaminepentaacetate (Magnevist). To date, 11 contrast agents have been approved by the US Food and Drug Administration for intravenous use. Coordination chemists have done a great deal to move the field forward. Our understanding of lanthanide chemistry now makes possible the design of complexes with long rotational correlation times, fast or slow water-exchange rates, high thermodynamic stabilities, and kinetic inertness, leading to sensitive and nontoxic contrast agents. Chemists did not stop there. The last few decades has seen the development of novel classes of probes that yield contrast through different mechanisms, such as paramagnetic chemical exchange saturation transfer agents. Thirty years since the first patent, chemists are still leading the way. The development of high-sensitivity contrast agents for high magnetic fields, safe probes for patients with kidney disorders, and multimodal, targeted, and responsive agents demonstrates that the field of contrast agents for MRI still has much to offer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.